NASDAQ:ENSC Ensysce Biosciences (ENSC) Stock Price, News & Analysis $0.43 +0.01 (+2.39%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.40▼$0.4350-Day Range$0.40▼$0.7452-Week Range$0.37▼$2.20Volume93,471 shsAverage Volume728,438 shsMarket Capitalization$3.25 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Ensysce Biosciences alerts: Email Address Ensysce Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,535.9% Upside$7.00 Price TargetShort InterestHealthy3.15% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.63) to ($1.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.13 out of 5 stars 3.5 Analyst's Opinion Consensus RatingEnsysce Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnsysce Biosciences has received no research coverage in the past 90 days.Read more about Ensysce Biosciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.15% of the float of Ensysce Biosciences has been sold short.Short Interest Ratio / Days to CoverEnsysce Biosciences has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ensysce Biosciences has recently decreased by 16.59%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnsysce Biosciences does not currently pay a dividend.Dividend GrowthEnsysce Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENSC. Previous Next 2.6 News and Social Media Coverage News SentimentEnsysce Biosciences has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Ensysce Biosciences this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for ENSC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Ensysce Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ensysce Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders52.70% of the stock of Ensysce Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.63% of the stock of Ensysce Biosciences is held by institutions.Read more about Ensysce Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ensysce Biosciences are expected to grow in the coming year, from ($1.63) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ensysce Biosciences is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ensysce Biosciences is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Ensysce Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHeard about the 72-Hour Profit Surge? Read this…One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…Click here now to get all the details. About Ensysce Biosciences Stock (NASDAQ:ENSC)Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.Read More ENSC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENSC Stock News HeadlinesJuly 24 at 3:52 AM | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Provides Mid-Year 2024 UpdateJune 24, 2024 | investorplace.comENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q1 2024July 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 20, 2024 | finance.yahoo.comSector Update: Health Care Stocks Softer Late AfternoonMay 14, 2024 | finance.yahoo.comEnsysce Biosciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 13, 2024 | msn.comENSC: Quarterly Report Highlights ProgressApril 25, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences' CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge MagazineApril 25, 2024 | finance.yahoo.comEnsysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge MagazineJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.April 9, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceMarch 18, 2024 | investorplace.comENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023March 15, 2024 | finance.yahoo.comENSC Striding Toward Opioid ReplacementMarch 15, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 21, 2024 | benzinga.comEnsysce Biosciences Stock (NASDAQ:ENSC), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comEnsysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose ProtectionFebruary 16, 2024 | finance.yahoo.comENSC: Investors Should Pay AttentionFebruary 15, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Announces Publication of Clinical Bioequivalence ManuscriptFebruary 15, 2024 | finance.yahoo.comEnsysce Biosciences Announces Publication of Clinical Bioequivalence ManuscriptSee More Headlines Receive ENSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/26/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ENSC CUSIPN/A CIK1716947 Webensysce.com Phone858-263-4196FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+1,516.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,610,000.00 Net Margins-660.96% Pretax Margin-661.19% Return on Equity-598.21% Return on Assets-266.08% Debt Debt-to-Equity RatioN/A Current Ratio2.87 Quick Ratio2.87 Sales & Book Value Annual Sales$2.23 million Price / Sales1.47 Cash FlowN/A Price / Cash FlowN/A Book Value($0.21) per share Price / Book-2.06Miscellaneous Outstanding Shares7,590,000Free Float3,588,000Market Cap$3.29 million OptionableNot Optionable Beta0.85 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. D. Lynn Kirkpatrick Ph.D. (Age 67)President, CEO & Director Comp: $414.77kMr. David C. Humphrey CPA (Age 55)CFO, Secretary & Treasurer Comp: $348.15kMr. Geoffrey Birkett (Age 61)Chief Commercial Officer Comp: $322kDr. Jeffrey Millard Ph.d. (Age 48)Chief Operating Officer Dr. William K. Schmidt Ph.D. (Age 73)Chairman of Clinical Advisory Board & Chief Medical Officer Dr. Linda Pestano Ph.D. (Age 54)Chief Development Officer More ExecutivesKey CompetitorsKiora PharmaceuticalsNASDAQ:KPRXAvalo TherapeuticsNASDAQ:AVTXVaxxinityNASDAQ:VAXXChemomab TherapeuticsNASDAQ:CMMBGuardion Health SciencesNASDAQ:GHSIView All Competitors ENSC Stock Analysis - Frequently Asked Questions How have ENSC shares performed this year? Ensysce Biosciences' stock was trading at $1.06 on January 1st, 2024. Since then, ENSC shares have decreased by 59.6% and is now trading at $0.4279. View the best growth stocks for 2024 here. How were Ensysce Biosciences' earnings last quarter? Ensysce Biosciences, Inc. (NASDAQ:ENSC) issued its quarterly earnings results on Friday, May, 10th. The company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.90) by $0.35. The firm had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.40 million. Ensysce Biosciences had a negative net margin of 660.96% and a negative trailing twelve-month return on equity of 598.21%. When did Ensysce Biosciences' stock split? Ensysce Biosciences shares reverse split before market open on Friday, March 31st 2023. The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Ensysce Biosciences? Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENSC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ensysce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.